Global Renal Denervation Market valued at $140 Million in 2022, is growing at a lucrative CAGR of 40% - Key Industry Players are Medtronic, Boston Scientific, St. Jude Medical (Abbott), ReCor Medical, Terumo

Resistant hypertension is a blood pressure which remains elevated above target levels despite the use of anti-hypertensive medications. About 12-15% of the population treated for high blood pressure suffers from resistant hypertension. Renal denervation is a minimally invasive procedure which is used to treat resistant hypertension. As the geriatric population of the world is growing, the number of people suffering from hypertension and the resistant hypertension is also increasing which is driving the growth of the renal denervation market.

Increasing Prevalence of Hypertension is driving the growth of the Renal Denervation Market

According to WHO, currently more than 1 billion people across the world are suffering from hypertension which is expected to grow to 1.6 billion by 2025. WHO estimated that less than one in five people have their hypertension under control, either due to non-adherence or resistance to medication. This is leading to the growing prevalence of hypertension/resistant hypertension, thereby driving the demand and growth of the renal denervation market.

Lack of long-term Clinical Data and Risks associated with the RDN procedures triggers the Renal Denervation Market

Though Renal Denervation is perceived as a potential treatment for resistant hypertension, it is a relatively new procedure and less data is available on its long-term side-effects. Owing to the limited clinical evidence, the RDN products are available only for investigational purpose in some of the major regions.

For instance, Medtronic's Symplicity Spyral RDN System's usage is limited only to investigational purpose in the US, Japan, and Canada. Further, there are various risks associated with this procedure which limits its applications. Some patients experience bradycardia during the procedure. The RF ablation may cause changes to the wall of the arteries, which can sometimes lead to renal artery stenosis. The imaging used during this procedure also has a number of risks associated with it. Other complications include tearing in the renal arteries and pseudoaneurysm (a bruise caused by a leaking hole in an artery).

Geographic Analysis: North America to offer ample growth opportunities in Renal Denervation Market

From a geographic perspective, Europe is the single largest renal denervation market. This is mainly attributed to the growing aging population, an increasing prevalence of hypertension, and higher penetration due to commercial availability of RDN products within Europe. The North American market is at a nascent stage as the RDN companies are yet to launch the products for commercial use in the region. However, the companies operating in the renal denervation market are thriving to introduce their products in the US market and are increasing their efforts on getting the commercial approvals.

For instance, Medtronic is likely to publish its results of SPYRAL HTN-ON MED clinical trials for its RDN system in the U.S. in later half of 2022. Further, in March 2022, ReCor Medical (Otsuka) completed subject enrolment for its RADIANCE-II pivotal trial of its Paradise Ultrasound Renal Denervation (uRDN) System for generating clinical trial data to enter the U.S. renal denervation market.

Competitive Landscape Analysis: Renal Denervation Market

Someof the established players operating in the global renal denervation market are Medtronic, Boston Scientific Corporation, St. Jude Medical (Abbott), ReCor Medical (Otsuka), and Terumo Corporation, among others.

Get Detailed Insights on Renal Denervation Market with a Sample Report PDF @ https://meditechinsights.com/global-renal-denervation-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.